Bath & Body Works (NYSE:BBWI) Stock Price Down 8% - Here's What Happened

Key Points

• Shares fell 8% on Friday to about $20.51 with volume sharply below average (1.08M vs. a 5.12M average), driving the stock to multi‑year lows despite recent news flow.
• Bath & Body Works beat Q4 estimates (EPS $2.05 vs. $1.77) and unveiled a "Consumer First" growth plan that prompted several analyst target increases, though management warns execution will take time and consensus sentiment remains largely cautious.
• Numerous securities‑fraud class actions and active plaintiff‑firm solicitations have surfaced, creating elevated legal risk and near‑term investor anxiety that likely weighed on the stock.

Bath & Body Works, Inc. (NYSE:BBWI - Get Free Report) shares fell 8% on Friday . The company traded as low as $20.47 and last traded at $20.51. 1,083,412 shares traded hands during trading, a decline of 79% from the average session volume of 5,124,963 shares. The stock had previously closed at $22.29.

Key Stories Impacting Bath & Body Works

Here are the key news stories impacting Bath & Body Works this week:

• Positive Sentiment: Q4 beat and growth plan — Bath & Body Works posted Q4 EPS of $2.05 vs. $1.77 expected and revenue above consensus; management rolled out its "Consumer First" strategy aimed at stabilizing growth. This supports near‑term fundamentals and prompted some analyst upgrades. Zacks: BBWI beats on Q4
• Positive Sentiment: Analysts lift forecasts and price targets — Several shops raised estimates/targets after results (Telsey raised its target to $25 with a market‑perform rating; Deutsche Bank and others nudged targets higher), signaling some confidence in the recovery trajectory. Benzinga: Analysts raise forecasts
• Neutral Sentiment: Mixed broker views — Barclays reaffirmed a "hold" on BBWI (neutral stance) even as some firms raised targets, leaving consensus sentiment cautious rather than outright bullish. Globe and Mail: Barclays hold
• Neutral Sentiment: Execution still in progress — Management says the strategy shift is making progress but "will take time," so investors face a runway of execution risk before material improvement in top‑line trends. MSN: Strategy shift progress
• Negative Sentiment: Numerous securities‑fraud class actions and plaintiff‑firm solicitations — Multiple law firms (Schall, Rosen, Pomerantz, DJS, Bragar Eagel & Squire, Bernstein Liebhard, Bronstein, etc.) have filed or are soliciting lead plaintiffs for alleged misstatements covering June 4, 2024–Nov 19, 2025, with upcoming lead‑plaintiff deadlines. The proliferation of filings increases legal risk, potential future costs, and near‑term investor anxiety. PR Newswire: Schall Law Firm notice
• Negative Sentiment: Broad litigation reminders compound selling pressure — Additional prominent firms are actively recruiting claimants and noting short deadlines, keeping the litigation story front‑and‑center for investors and likely weighing on sentiment until resolved. GlobeNewswire: Rosen Law Firm deadline

Analyst Upgrades and Downgrades

A number of analysts recently commented on BBWI shares. Citigroup cut Bath & Body Works from a "buy" rating to a "neutral" rating and upped their price objective for the company from $21.00 to $25.00 in a research report on Tuesday, February 17th. Robert W. Baird set a $20.00 price target on shares of Bath & Body Works in a research report on Wednesday, December 17th. JPMorgan Chase & Co. dropped their price objective on shares of Bath & Body Works from $26.00 to $15.00 and set a "neutral" rating on the stock in a report on Thursday, November 20th. Weiss Ratings restated a "hold (c-)" rating on shares of Bath & Body Works in a research report on Wednesday, January 21st. Finally, UBS Group increased their price target on shares of Bath & Body Works from $21.00 to $22.00 and gave the stock a "neutral" rating in a research report on Monday, February 23rd. Three investment analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company. According to data from MarketBeat, Bath & Body Works presently has an average rating of "Hold" and an average price target of $24.00.

Bath & Body Works Stock Performance

The stock has a fifty day moving average of $22.37 and a 200 day moving average of $23.58. The company has a market capitalization of $4.25 billion, a PE ratio of 6.58, a PEG ratio of 0.97 and a beta of 1.48.

Bath & Body Works (NYSE:BBWI - Get Free Report) last released its quarterly earnings data on Wednesday, March 4th. The company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.28. Bath & Body Works had a net margin of 8.90% and a negative return on equity of 45.60%. The firm had revenue of $2.72 billion for the quarter, compared to analysts' expectations of $2.59 billion. During the same quarter last year, the business posted $2.09 earnings per share. The company's revenue for the quarter was down 2.3% compared to the same quarter last year. Bath & Body Works has set its Q1 2026 guidance at 0.240-0.300 EPS and its FY 2026 guidance at 2.400-2.650 EPS. As a group, equities analysts predict that Bath & Body Works, Inc. will post 3.3 EPS for the current year.

Bath & Body Works Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 20th will be issued a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 3.9%. The ex-dividend date of this dividend is Friday, February 20th. Bath & Body Works's payout ratio is 25.40%.

Hedge Funds Weigh In On Bath & Body Works

Several institutional investors have recently added to or reduced their stakes in BBWI. AQR Capital Management LLC raised its holdings in shares of Bath & Body Works by 132.5% during the 4th quarter. AQR Capital Management LLC now owns 11,445,928 shares of the company's stock worth $229,834,000 after acquiring an additional 6,523,960 shares in the last quarter. JPMorgan Chase & Co. increased its position in Bath & Body Works by 11.5% in the second quarter. JPMorgan Chase & Co. now owns 7,080,106 shares of the company's stock worth $212,120,000 after purchasing an additional 733,000 shares during the last quarter. Alliancebernstein L.P. increased its position in Bath & Body Works by 2.2% in the third quarter. Alliancebernstein L.P. now owns 5,861,444 shares of the company's stock worth $150,991,000 after purchasing an additional 123,648 shares during the last quarter. Cooper Creek Partners Management LLC raised its stake in Bath & Body Works by 42.7% during the second quarter. Cooper Creek Partners Management LLC now owns 5,409,919 shares of the company's stock valued at $162,081,000 after purchasing an additional 1,619,276 shares in the last quarter. Finally, American Century Companies Inc. lifted its position in Bath & Body Works by 2,204.1% during the third quarter. American Century Companies Inc. now owns 5,174,370 shares of the company's stock valued at $133,292,000 after purchasing an additional 4,949,796 shares during the last quarter. Hedge funds and other institutional investors own 95.14% of the company's stock.

Bath & Body Works Company Profile

Bath & Body Works, Inc is a leading specialty retailer focused on personal care, home fragrance and complementary products. Through its flagship Bath & Body Works brand, the company offers a diverse assortment of shower gels, lotions, fragrance mists, candles and home fragrance items. Its product portfolio also includes the White Barn Candle Co range of premium scented candles and diffusers. Bath & Body Works serves consumers through a combination of brick-and-mortar stores and e-commerce platforms, delivering seasonal collections, limited-edition releases and signature scent lines.

Founded in 1990 as part of Limited Brands (now L Brands), Bath & Body Works opened its first store in New Albany, Ohio, and quickly expanded across the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.